Profound Medical Corp (NAS:PROF)
$ 7.15 0.1 (1.42%) Market Cap: 209.63 Mil Enterprise Value: 188.61 Mil PE Ratio: 0 PB Ratio: 5.93 GF Score: 73/100

Profound Medical Corp at Bloom Burton & Co. Healthcare Investor Conference Transcript

May 02, 2022 / 06:00PM GMT
Release Date Price: $7.62 (+4.38%)
Unidentified Participant

Today, we have Arun Menawat, CEO and Chairman of the Board of Profound Medical.

Arun Menawat
Profound Medical Corp. - CEO & Chairman of the Board

All right. Good afternoon, and thank you for Bloom Burton for such a wonderful conference that you hold. I am delighted to be here. I am delighted to talk about Profound.

As you may know, we are about game-changing technology, and we actually think that the type of technologies that we are developing are likely to be the future way of doing many, many types of procedures, which can be incision-free, radiation-free procedures.

So I'm going to start with our primary product today. We have phenomenal disclosures, and I encourage you to highly read, particularly the COVID-19 one, every word. And if you see any spelling mistakes, let me know please.

So TULSA-PRO is our primary product. We received FDA clearance in August 2019. We introduced the product in the United States in the first quarter of 2020. Obviously, COVID hit the same quarter. And we really created a very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot